MTOR and chronic myelogenous leukemia, BCR-ABL1 positive: The potential of mTOR has been discussed in chronic myeloid leukemia (CML) and acute myeloid leukemia (AML) since it is known that activation of the mTOR pathway is associated with deregulated production of malignant lymphoid cells and chemotherapeutic resistance in acute lymphoblastic leukemia (ALL).